Colestipol hydrochloride

CLINICAL USE

Hyperlipidaemias, particularly type IIa

DOSE IN NORMAL RENAL FUNCTION

5 g once or twice daily, increased if necessary at intervals of 1–2 months, to a maximum of 30 g daily

PHARMACOKINETICS

Molecular weight :–

%Protein binding :0

%Excreted unchanged in urine : 0

Volume of distribution (L/kg) :Not absorbed

half-life – normal/ESRD (hrs) :Not absorbed

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Not dialysed. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAnticoagulants: may enhance or reduce effects of coumarins and phenindioneCiclosporin: No reports of an interaction; however, ciclosporin levels should be carefully monitored if colestipol and ciclosporin are prescribed concurrently, as colestipol may interfere with ciclosporin absorption

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorptionColestipol granules may be administered as a suspension in water or a flavoured vehicleColestipol orange contains 32.5 mg aspartame (18.2 mg phenylalanine) per sachet

OTHER INFORMATION

Colestipol may interfere with the absorption of fat soluble vitamins

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home